{"id":4936,"date":"2023-10-30T10:12:51","date_gmt":"2023-10-30T09:12:51","guid":{"rendered":"https:\/\/afcytometrie.fr\/evenement\/groupe-cytometrie-de-masse-afc-caracterisation-des-lymphocytes-t-regulateur-dans-le-cancer-du-poumon\/"},"modified":"2023-10-30T10:25:09","modified_gmt":"2023-10-30T09:25:09","slug":"groupe-cytometrie-de-masse-afc-caracterisation-des-lymphocytes-t-regulateur-dans-le-cancer-du-poumon","status":"publish","type":"evenement","link":"https:\/\/afcytometrie.fr\/en\/evenement\/groupe-cytometrie-de-masse-afc-caracterisation-des-lymphocytes-t-regulateur-dans-le-cancer-du-poumon\/","title":{"rendered":"Mass Cytometry group AFC : Characterization of Regulatory T Lymphocytes in Breast Cancers"},"content":{"rendered":"\n
\n
\n
\n
\"\"<\/figure>\n<\/div><\/div>\n<\/div>\n<\/div>\n\n\n\n

The Mass Cytometry Group of the French Cytometry Association Invites you to its Webinar <\/p>\n\n\n\n

Tuesday November 7, 2023 at 12:30 p.m<\/p>\n\n\n\n

Characterization of Regulatory T Lymphocytes in Breast Cancer<\/strong><\/p>\n\n\n\n

Presented by Stephane Fattori<\/strong><\/p>\n\n\n\n

Immunomonitoring department, Pauli Calmettes Institute, CRM, Marseille<\/p>\n\n\n\n

Zoom link : https:\/\/univ amu fr.zoom.us\/j\/86931336119?pwd= TEgzb01ZM0FucFhKb3hEdmk5VEpKZz09<\/a>
Login code: 725552<\/p>\n\n\n\n

Abstract :<\/em><\/strong>
Triple negative breast cancer (TNBC) is the deadliest subtype of breast cancer Standard treatments for
patients with early stage, locally advanced or metastatic TNBC include the combination of neoadjuvant
chemotherapy and pembrolizumab, an immune checkpoint blockade targeting the programmed cell
death 1 (PD-1) receptor PD-1 blockade reinvigorate tumor antigen specific CD8+ T cells in primary TNBC.
However, approximately 40 and 80 of early stage and advanced or metastatic TNBC are resistant to
PD 1 blockade therapy, respectively.
Regulatory T cells (Tregs) are an immunosuppressive subset of CD4+ T cells essential for maintaining self
tolerance in physiological settings. Abundant tumor infiltration by Tregs harbouring hallmarks of highly
suppressive CD25high effector Tregs (eTregs) has been associated with resistance to PD 1 blockade in
cancer indications for which pembrolizumab was approved much earlier than for TNBC, such as non
small cell lung cancer. In contrast, in TNBC, the prognostic value of intratumoral Tregs remains
controversial and no association between baseline levels of eTregs and responses to PD 1 blockade
therapy has been reported, despite the clinical significance of this cancer indication. In the present
thesis, we used single cell technologies to dissect the nature and function of eTreg during TNBC
progression. We found that an immunosuppressive TNBC microenvironment resistant to PD-1 blockade
therapy is marked by an imbalance between effector CD8+ T cells and CD25 high eTregs. We further
identified CD25 as the most selective surface marker of eTregs in primary TNBC and associated
metastases for limited on target\/off target effects. In a syngeneic TNBC model, selective Treg depletion
by a next generation anti-CD25 monoclonal antibody (mAb; ALD 2510; Alderaan Biotechnology)
synergized with PD-1 blockade to safely mediate durable tumor growth control by increasing effector
\u03b1\u03b2CD8+ T cell\/Treg ratios in tumors and in the peripheral blood Overall, we propose that Treg depletion
by next generation anti-CD25 mAb could improve clinical responses to PD-1 blockade therapy in patients
with TNBC at different stage of the disease<\/p>\n","protected":false},"template":"","typesevenement":[58],"class_list":["post-4936","evenement","type-evenement","status-publish","hentry","typesevenement-webinars-groupes-thematiques-en"],"acf":[],"yoast_head":"\nMass Cytometry group AFC : Characterization of Regulatory T Lymphocytes in Breast Cancers - AFC<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/afcytometrie.fr\/en\/evenement\/groupe-cytometrie-de-masse-afc-caracterisation-des-lymphocytes-t-regulateur-dans-le-cancer-du-poumon\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mass Cytometry group AFC : Characterization of Regulatory T Lymphocytes in Breast Cancers - AFC\" \/>\n<meta property=\"og:description\" content=\"The Mass Cytometry Group of the French Cytometry Association Invites you to its Webinar Tuesday November 7, 2023 at 12:30 p.m Characterization of Regulatory T Lymphocytes in Breast Cancer Presented by Stephane Fattori Immunomonitoring department, Pauli Calmettes Institute, CRM, Marseille Zoom link : https:\/\/univ amu fr.zoom.us\/j\/86931336119?pwd= TEgzb01ZM0FucFhKb3hEdmk5VEpKZz09Login code: 725552 Abstract :Triple negative breast cancer (TNBC) is the deadliest subtype of breast cancer Standard treatments forpatients with early stage, locally advanced or metastatic TNBC include the combination of neoadjuvantchemotherapy and pembrolizumab, an immune checkpoint blockade targeting the programmed celldeath 1 (PD-1) receptor PD-1 blockade reinvigorate tumor antigen specific CD8+ T cells in primary TNBC.However, approximately 40 and 80 of early stage and advanced or metastatic TNBC are resistant toPD 1 blockade therapy, respectively.Regulatory T cells (Tregs) are an immunosuppressive subset of CD4+ T cells essential for maintaining selftolerance in physiological settings. Abundant tumor infiltration by Tregs harbouring hallmarks of highlysuppressive CD25high effector Tregs (eTregs) has been associated with resistance to PD 1 blockade incancer indications for which pembrolizumab was approved much earlier than for TNBC, such as nonsmall cell lung cancer. In contrast, in TNBC, the prognostic value of intratumoral Tregs remainscontroversial and no association between baseline levels of eTregs and […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/afcytometrie.fr\/en\/evenement\/groupe-cytometrie-de-masse-afc-caracterisation-des-lymphocytes-t-regulateur-dans-le-cancer-du-poumon\/\" \/>\n<meta property=\"og:site_name\" content=\"AFC\" \/>\n<meta property=\"article:modified_time\" content=\"2023-10-30T09:25:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/afcytometrie.fr\/wp-content\/uploads\/2023\/05\/image-1-1024x657.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/afcytometrie.fr\/en\/evenement\/groupe-cytometrie-de-masse-afc-caracterisation-des-lymphocytes-t-regulateur-dans-le-cancer-du-poumon\/\",\"url\":\"https:\/\/afcytometrie.fr\/en\/evenement\/groupe-cytometrie-de-masse-afc-caracterisation-des-lymphocytes-t-regulateur-dans-le-cancer-du-poumon\/\",\"name\":\"Mass Cytometry group AFC : Characterization of Regulatory T Lymphocytes in Breast Cancers - AFC\",\"isPartOf\":{\"@id\":\"https:\/\/afcytometrie.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/afcytometrie.fr\/en\/evenement\/groupe-cytometrie-de-masse-afc-caracterisation-des-lymphocytes-t-regulateur-dans-le-cancer-du-poumon\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/afcytometrie.fr\/en\/evenement\/groupe-cytometrie-de-masse-afc-caracterisation-des-lymphocytes-t-regulateur-dans-le-cancer-du-poumon\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/afcytometrie.fr\/wp-content\/uploads\/2023\/05\/image-1-1024x657.png\",\"datePublished\":\"2023-10-30T09:12:51+00:00\",\"dateModified\":\"2023-10-30T09:25:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/afcytometrie.fr\/en\/evenement\/groupe-cytometrie-de-masse-afc-caracterisation-des-lymphocytes-t-regulateur-dans-le-cancer-du-poumon\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/afcytometrie.fr\/en\/evenement\/groupe-cytometrie-de-masse-afc-caracterisation-des-lymphocytes-t-regulateur-dans-le-cancer-du-poumon\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/afcytometrie.fr\/en\/evenement\/groupe-cytometrie-de-masse-afc-caracterisation-des-lymphocytes-t-regulateur-dans-le-cancer-du-poumon\/#primaryimage\",\"url\":\"https:\/\/afcytometrie.fr\/wp-content\/uploads\/2023\/05\/image-1-1024x657.png\",\"contentUrl\":\"https:\/\/afcytometrie.fr\/wp-content\/uploads\/2023\/05\/image-1-1024x657.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/afcytometrie.fr\/en\/evenement\/groupe-cytometrie-de-masse-afc-caracterisation-des-lymphocytes-t-regulateur-dans-le-cancer-du-poumon\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Ev\u00e9nements\",\"item\":\"https:\/\/afcytometrie.fr\/en\/evenements\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mass Cytometry group AFC : Characterization of Regulatory T Lymphocytes in Breast Cancers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/afcytometrie.fr\/en\/#website\",\"url\":\"https:\/\/afcytometrie.fr\/en\/\",\"name\":\"AFC\",\"description\":\"Un site utilisant WordPress\",\"publisher\":{\"@id\":\"https:\/\/afcytometrie.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/afcytometrie.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/afcytometrie.fr\/en\/#organization\",\"name\":\"AFC\",\"url\":\"https:\/\/afcytometrie.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/afcytometrie.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/afcytometrie.fr\/wp-content\/uploads\/2021\/05\/logo-AFC.jpg\",\"contentUrl\":\"https:\/\/afcytometrie.fr\/wp-content\/uploads\/2021\/05\/logo-AFC.jpg\",\"width\":240,\"height\":87,\"caption\":\"AFC\"},\"image\":{\"@id\":\"https:\/\/afcytometrie.fr\/en\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mass Cytometry group AFC : Characterization of Regulatory T Lymphocytes in Breast Cancers - AFC","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/afcytometrie.fr\/en\/evenement\/groupe-cytometrie-de-masse-afc-caracterisation-des-lymphocytes-t-regulateur-dans-le-cancer-du-poumon\/","og_locale":"en_US","og_type":"article","og_title":"Mass Cytometry group AFC : Characterization of Regulatory T Lymphocytes in Breast Cancers - AFC","og_description":"The Mass Cytometry Group of the French Cytometry Association Invites you to its Webinar Tuesday November 7, 2023 at 12:30 p.m Characterization of Regulatory T Lymphocytes in Breast Cancer Presented by Stephane Fattori Immunomonitoring department, Pauli Calmettes Institute, CRM, Marseille Zoom link : https:\/\/univ amu fr.zoom.us\/j\/86931336119?pwd= TEgzb01ZM0FucFhKb3hEdmk5VEpKZz09Login code: 725552 Abstract :Triple negative breast cancer (TNBC) is the deadliest subtype of breast cancer Standard treatments forpatients with early stage, locally advanced or metastatic TNBC include the combination of neoadjuvantchemotherapy and pembrolizumab, an immune checkpoint blockade targeting the programmed celldeath 1 (PD-1) receptor PD-1 blockade reinvigorate tumor antigen specific CD8+ T cells in primary TNBC.However, approximately 40 and 80 of early stage and advanced or metastatic TNBC are resistant toPD 1 blockade therapy, respectively.Regulatory T cells (Tregs) are an immunosuppressive subset of CD4+ T cells essential for maintaining selftolerance in physiological settings. Abundant tumor infiltration by Tregs harbouring hallmarks of highlysuppressive CD25high effector Tregs (eTregs) has been associated with resistance to PD 1 blockade incancer indications for which pembrolizumab was approved much earlier than for TNBC, such as nonsmall cell lung cancer. In contrast, in TNBC, the prognostic value of intratumoral Tregs remainscontroversial and no association between baseline levels of eTregs and […]","og_url":"https:\/\/afcytometrie.fr\/en\/evenement\/groupe-cytometrie-de-masse-afc-caracterisation-des-lymphocytes-t-regulateur-dans-le-cancer-du-poumon\/","og_site_name":"AFC","article_modified_time":"2023-10-30T09:25:09+00:00","og_image":[{"url":"https:\/\/afcytometrie.fr\/wp-content\/uploads\/2023\/05\/image-1-1024x657.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/afcytometrie.fr\/en\/evenement\/groupe-cytometrie-de-masse-afc-caracterisation-des-lymphocytes-t-regulateur-dans-le-cancer-du-poumon\/","url":"https:\/\/afcytometrie.fr\/en\/evenement\/groupe-cytometrie-de-masse-afc-caracterisation-des-lymphocytes-t-regulateur-dans-le-cancer-du-poumon\/","name":"Mass Cytometry group AFC : Characterization of Regulatory T Lymphocytes in Breast Cancers - AFC","isPartOf":{"@id":"https:\/\/afcytometrie.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/afcytometrie.fr\/en\/evenement\/groupe-cytometrie-de-masse-afc-caracterisation-des-lymphocytes-t-regulateur-dans-le-cancer-du-poumon\/#primaryimage"},"image":{"@id":"https:\/\/afcytometrie.fr\/en\/evenement\/groupe-cytometrie-de-masse-afc-caracterisation-des-lymphocytes-t-regulateur-dans-le-cancer-du-poumon\/#primaryimage"},"thumbnailUrl":"https:\/\/afcytometrie.fr\/wp-content\/uploads\/2023\/05\/image-1-1024x657.png","datePublished":"2023-10-30T09:12:51+00:00","dateModified":"2023-10-30T09:25:09+00:00","breadcrumb":{"@id":"https:\/\/afcytometrie.fr\/en\/evenement\/groupe-cytometrie-de-masse-afc-caracterisation-des-lymphocytes-t-regulateur-dans-le-cancer-du-poumon\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/afcytometrie.fr\/en\/evenement\/groupe-cytometrie-de-masse-afc-caracterisation-des-lymphocytes-t-regulateur-dans-le-cancer-du-poumon\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/afcytometrie.fr\/en\/evenement\/groupe-cytometrie-de-masse-afc-caracterisation-des-lymphocytes-t-regulateur-dans-le-cancer-du-poumon\/#primaryimage","url":"https:\/\/afcytometrie.fr\/wp-content\/uploads\/2023\/05\/image-1-1024x657.png","contentUrl":"https:\/\/afcytometrie.fr\/wp-content\/uploads\/2023\/05\/image-1-1024x657.png"},{"@type":"BreadcrumbList","@id":"https:\/\/afcytometrie.fr\/en\/evenement\/groupe-cytometrie-de-masse-afc-caracterisation-des-lymphocytes-t-regulateur-dans-le-cancer-du-poumon\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Ev\u00e9nements","item":"https:\/\/afcytometrie.fr\/en\/evenements\/"},{"@type":"ListItem","position":2,"name":"Mass Cytometry group AFC : Characterization of Regulatory T Lymphocytes in Breast Cancers"}]},{"@type":"WebSite","@id":"https:\/\/afcytometrie.fr\/en\/#website","url":"https:\/\/afcytometrie.fr\/en\/","name":"AFC","description":"Un site utilisant WordPress","publisher":{"@id":"https:\/\/afcytometrie.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/afcytometrie.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/afcytometrie.fr\/en\/#organization","name":"AFC","url":"https:\/\/afcytometrie.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/afcytometrie.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/afcytometrie.fr\/wp-content\/uploads\/2021\/05\/logo-AFC.jpg","contentUrl":"https:\/\/afcytometrie.fr\/wp-content\/uploads\/2021\/05\/logo-AFC.jpg","width":240,"height":87,"caption":"AFC"},"image":{"@id":"https:\/\/afcytometrie.fr\/en\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/afcytometrie.fr\/en\/wp-json\/wp\/v2\/evenement\/4936","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/afcytometrie.fr\/en\/wp-json\/wp\/v2\/evenement"}],"about":[{"href":"https:\/\/afcytometrie.fr\/en\/wp-json\/wp\/v2\/types\/evenement"}],"wp:attachment":[{"href":"https:\/\/afcytometrie.fr\/en\/wp-json\/wp\/v2\/media?parent=4936"}],"wp:term":[{"taxonomy":"typesevenement","embeddable":true,"href":"https:\/\/afcytometrie.fr\/en\/wp-json\/wp\/v2\/typesevenement?post=4936"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}